AngioDynamics (NASDAQ:ANGO) Coverage Initiated at Lake Street Capital

Equities researchers at Lake Street Capital initiated coverage on shares of AngioDynamics (NASDAQ:ANGO - Get Free Report) in a report issued on Wednesday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $24.00 price target on the medical instruments supplier's stock. Lake Street Capital's price target points to a potential upside of 173.97% from the company's previous close.

ANGO has been the subject of a number of other reports. Canaccord Genuity Group raised their target price on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a report on Wednesday.

AngioDynamics Trading Up 1.3%

Shares of NASDAQ:ANGO traded up $0.11 during midday trading on Wednesday, reaching $8.76. The company had a trading volume of 233,854 shares, compared to its average volume of 594,609. The company's 50 day moving average price is $9.88 and its 200 day moving average price is $10.08. The stock has a market cap of $355.74 million, a P/E ratio of -8.62 and a beta of 0.60. AngioDynamics has a 52-week low of $5.83 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.09. The company had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. AngioDynamics had a negative net margin of 14.61% and a negative return on equity of 3.73%. AngioDynamics's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.06) earnings per share. Research analysts forecast that AngioDynamics will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently bought and sold shares of the company. Systematic Financial Management LP boosted its position in AngioDynamics by 4.6% in the 4th quarter. Systematic Financial Management LP now owns 2,521,065 shares of the medical instruments supplier's stock worth $23,093,000 after purchasing an additional 110,719 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of AngioDynamics by 8.7% during the 1st quarter. Vanguard Group Inc. now owns 2,492,563 shares of the medical instruments supplier's stock valued at $23,405,000 after buying an additional 199,944 shares in the last quarter. Armistice Capital LLC lifted its position in shares of AngioDynamics by 140.1% during the 1st quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier's stock valued at $19,663,000 after buying an additional 1,222,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of AngioDynamics by 10.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,488,667 shares of the medical instruments supplier's stock valued at $13,636,000 after buying an additional 135,007 shares in the last quarter. Finally, Segall Bryant & Hamill LLC lifted its position in shares of AngioDynamics by 55.3% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier's stock valued at $12,963,000 after buying an additional 503,713 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.